Codexis Inc (NASDAQ: CDXS)’s stock price has soared by 17.08% in relation to previous closing price of $2.4. Nevertheless, the company has seen a gain of 11.95% in its stock price over the last five trading days. globenewswire.com reported 2025-05-22 that Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Is It Worth Investing in Codexis Inc (NASDAQ: CDXS) Right Now?
The 36-month beta value for CDXS is also noteworthy at 2.54. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CDXS is 80.17M, and at present, short sellers hold a 7.93% of that float. The average trading volume of CDXS on July 03, 2025 was 855.10K shares.
CDXS’s Market Performance
CDXS’s stock has seen a 11.95% increase for the week, with a 24.89% rise in the past month and a 11.95% gain in the past quarter. The volatility ratio for the week is 7.82%, and the volatility levels for the past 30 days are at 6.84% for Codexis Inc The simple moving average for the last 20 days is 17.94% for CDXS’s stock, with a simple moving average of -17.72% for the last 200 days.
Analysts’ Opinion of CDXS
Jefferies, on the other hand, stated in their research note that they expect to see CDXS reach a price target of $5. The rating they have provided for CDXS stocks is “Buy” according to the report published on June 03rd, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to CDXS, setting the target price at $11 in the report published on May 30th of the previous year.
CDXS Trading at 17.74% from the 50-Day Moving Average
After a stumble in the market that brought CDXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.78% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXS starting from Opaleye Management Inc., who purchase 100,000 shares at the price of $2.39 back on Jun 27 ’25. After this action, Opaleye Management Inc. now owns 12,350,000 shares of Codexis Inc, valued at $239,000 using the latest closing price.
Opaleye Management Inc., the 10% Owner of Codexis Inc, purchase 100,000 shares at $2.25 during a trade that took place back on Jun 12 ’25, which means that Opaleye Management Inc. is holding 12,100,000 shares at $225,000 based on the most recent closing price.
Stock Fundamentals for CDXS
Current profitability levels for the company are sitting at:
- -1.34 for the present operating margin
- 0.69 for the gross margin
The net margin for Codexis Inc stands at -1.49. The total capital return value is set at 7.23. Equity return is now at value -115.53, with -53.48 for asset returns.
Based on Codexis Inc (CDXS), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at -0.93. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is 45.98.
Currently, EBITDA for the company is -58.52 million with net debt to EBITDA at -0.64. When we switch over and look at the enterprise to sales, we see a ratio of 5.5. The receivables turnover for the company is 5.06for trailing twelve months and the total asset turnover is 4.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.72.
Conclusion
In summary, Codexis Inc (CDXS) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
